Vitae regains rights to renin inhibitor program
Vitae Pharmaceuticals, an emerging US pharmaceutical company dedicated to the discovery and development of innovative small-molecule medicines, has reacquired full rights to its renin inhibitor program from GlaxoSmithKline.
"We are excited to regain full ownership and control of our promising renin program as we prepare to enter our lead compound into clinical trials in 2009," said chief executive Jeffrey Hatfield. "Renin continues to be a much sought-after target, and our team has been one of the few that has been able to generate highly potent and bioavailable inhibitors that we believe will lead to important drug candidates in this large market," he added.
Richard Gregg, chief scientific officer, said: "we expect to target hypertension, diabetic nephropathy, congestive heart failure and related cardiovascular indications after completing Investigational New Drug-enabling toxicity studies."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze